Miller V - Search Results

1

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A. Staszewski S, et al. Among authors: miller v. AIDS. 1999 May 28;13(8):951-6. doi: 10.1097/00002030-199905280-00011. AIDS. 1999. PMID: 10371176

2

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

Miller V, Staszewski S, Boucher CA, Phair JP. Miller V, et al. AIDS. 1997;11 Suppl A:S157-64. AIDS. 1997. PMID: 9451980 Review. No abstract available.

3

Rebound of HIV-1 viral load after suppression to very low levels.

Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN. Staszewski S, et al. Among authors: miller v. AIDS. 1998 Dec 3;12(17):2360. AIDS. 1998. PMID: 9863886 No abstract available.

4

Virological response to protease inhibitor therapy in an HIV clinic cohort.

Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A. Staszewski S, et al. Among authors: miller v. AIDS. 1999 Feb 25;13(3):367-73. doi: 10.1097/00002030-199902250-00009. AIDS. 1999. PMID: 10199227

5

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN. Miller V, et al. J Infect Dis. 1999 Aug;180(2):530-3. doi: 10.1086/314890. J Infect Dis. 1999. PMID: 10395876

6

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. Miller V, et al. AIDS. 2000 Sep 29;14(14):2129-36. doi: 10.1097/00002030-200009290-00009. AIDS. 2000. PMID: 11061654 Clinical Trial.

7

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Miller V, et al. AIDS. 2000 Dec 22;14(18):2857-67. doi: 10.1097/00002030-200012220-00007. AIDS. 2000. PMID: 11153667

8

The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.

Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. Lepri AC, et al. Among authors: miller v. AIDS. 2001 Jan 5;15(1):47-54. doi: 10.1097/00002030-200101050-00008. AIDS. 2001. PMID: 11192867

9

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.

Phillips AN, Miller V, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, Doerr HW, Hill A, Staszewski S. Phillips AN, et al. Among authors: miller v. AIDS. 2001 Dec 7;15(18):2379-84. doi: 10.1097/00002030-200112070-00005. AIDS. 2001. PMID: 11740188 Clinical Trial.

10

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

Staszewski S, Miller V, Rehmet S, Stark T, De Crée J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pearce G, Van den Broeck R, Verbiest W, Stoffels P. Staszewski S, et al. Among authors: miller v. AIDS. 1996 May;10(5):F1-7. doi: 10.1097/00002030-199605000-00001. AIDS. 1996. PMID: 8724034 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,955 results

Search Page

Filters